Table of Contents

 



 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

  

FORM 10-Q

(Mark One)

  

 

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

  

For the Quarterly Period Ended SeptemberJune 30, 20182019

  

oorr

  

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

  

For the Transition Period From                                to                                 .

  

Commission file number 000-25727

  

IKONICS CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota

41-0730027

(State or other jurisdiction of

incorporation or organization)

(I.R.S. employer

identification no.)

 

 

4832 Grand Avenue

Duluth, Minnesota

55807

(Address of principal executive offices)

(Zip code)

(218) 628-2217

(Registrant’s telephone number, including area code)

  

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

  

CheckSecurities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $.10 per share

IKNX

Nasdaq Capital Market

Indicate by check mark whether the issuerregistrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.)  Yes ☒  No ☐

    

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

 

StateIndicate the number of shares outstanding of each of the issuer’s classes of common equity,stock, as of the latest practicable date: Common Stock, $.10 par value per share - 1,983,5531,980,811 shares outstanding as of NovemberAugust 1, 2018.2019.

  



1

 

 

IKONICS CorporationCORPORATION 

  

QUARTERLY REPORT ON FORM 10-Q

  

 

 

PAGE NO.

PART I.

FINANCIAL INFORMATION

 

 

 

 

Item 1.

 

Condensed Financial Statements:

3

 

 

 

 

 

 

Condensed Balance Sheets as of SeptemberJune 30, 20182019 (unaudited) and December 31, 20172018

13

 

 

 

 

 

 

Condensed Statements of Operations for the Three Months and NineSix Months Ended SeptemberJune 30, 20182019 and 20172018 (unaudited)

24

 

 

 

 

Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2019 and 2018 (unaudited)5

 

 

Condensed Statements of Cash Flows for the NineSix Months Ended SeptemberJune 30, 20182019 and 20172018 (unaudited)

36

 

 

 

 

 

 

Notes to Condensed Financial Statements (unaudited)

47

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

1211

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures about Market Risk

1916

 

 

 

 

Item 4.

 

Controls and Procedures

1916

 

 

 

PART II.

OTHER INFORMATION

2017

 

 

 

 

SIGNATURES

2118

  

  

2

 

 

PART I - FINANCIAL INFORMATION

  

ITEM 1.  Condensed Financial Statements

  

IKONICS CORPORATION 

CONDENSED BALANCE SHEETS

 

 

September 30,

  

December 31,

 
 

2018

  

2017

  

June 30,

  

December 31,

 
 

(unaudited)

      

2019

  

2018

 

ASSETS

         

(unaudited)

     
        

CURRENT ASSETS:

                

Cash and cash equivalents

 $1,559,725  $929,700  $297,186  $1,623,137 

Short-term investments

  2,695,000   2,895,000   2,940,000   2,695,000 

Trade receivables, less allowance of $58,000 in 2018 and $53,000 in 2017

  1,975,741   2,190,260 

Trade receivables, less allowance of $53,000 in 2019 and 2018

  2,223,445   2,215,215 

Inventories

  2,270,890   2,086,065   2,512,249   2,046,588 

Prepaid expenses and other assets

  210,570   168,242   262,325   375,362 

Income taxes receivable

  10,208   2,116   185,219   2,768 

Total current assets

  8,722,134   8,271,383   8,420,424   8,958,070 
        

PROPERTY, PLANT, AND EQUIPMENT, at cost:

                

Land and building

  9,507,589   9,207,790   9,500,429   9,500,429 

Machinery and equipment

  5,110,666   4,968,595   5,132,719   4,964,816 

Office equipment

  1,583,524   1,573,191   1,565,456   1,559,728 

Vehicles

  245,679   245,679   245,674   245,679 
  16,447,458   15,995,255   16,444,278   16,270,652 

Less accumulated depreciation

  (8,232,338)  (7,693,594)  (8,457,143)  (8,185,910)

Total property, plant, and equipment, at cost

  8,215,120   8,301,661 

INTANGIBLE ASSETS, less accumulated amortization of $143,643 as of September 30, 2018 and $174,991 as of December 31, 2017

  368,823   351,186 

Total property, plant and equipment at cost, net

  7,987,135   8,084,742 
        

INTANGIBLE ASSETS, less accumulated amortization of $168,488 in 2019 and $149,740 in 2018

  292,380   376,406 

Total assets

 $17,306,077  $16,924,230  $16,699,939  $17,419,218 
        

LIABILITIES AND STOCKHOLDERS' EQUITY

                
        

CURRENT LIABILITIES

                

Current portion of long-term debt, net

 $128,247  $130,899 

Current portion of long-term debt

 $131,385  $129,282 

Accounts payable

  711,016   321,860   533,424   647,528 

Accrued compensation

  244,333   360,554   331,334   366,900 

Other accrued liabilities

  253,282   62,468   242,284   159,821 

Total current liabilities

  1,336,878   875,781   1,238,427   1,303,531 
        

LONG-TERM LIABILITIES

                

Long-term debt, less current portion, net

  2,854,529   2,946,518 

Long-term debt, less current portion

  2,755,353   2,821,657 

Deferred income taxes

  156,839   144,000   183,000   183,000 

Total long-term liabilities

  3,011,368   3,090,518   2,938,353   3,004,657 

Total liabilities

  4,348,246   3,966,299   4,176,780   4,308,188 

COMMITMENTS AND CONTINGENCIES

                

STOCKHOLDERS’ EQUITY

        

Preferred stock, par value $.10 per share; authorized 250,000 shares; none issued

      

Common stock, par value $.10 per share; authorized 4,750,000 shares; issued and outstanding 1,983,553 shares as of September 30, 2018 and December 31, 2017

  198,355   198,355 

Additional paid-in capital

  2,719,444   2,709,390 
        

STOCKHOLDERS' EQUITY

        
        

Preferred stock, par value $.10 per share; authorized 250,000 shares; issued none

      
        

Common stock, par value $.10 per share; authorized 4,750,000 shares; issued and outstanding 1,980,811 shares in 2019 and 1,983,553 in 2018.

  198,081   198,355 

Additional paid-in-capital

  2,723,099   2,723,024 

Retained earnings

  10,040,032   10,050,186   9,601,979   10,189,651 

Total stockholders’ equity

  12,957,831   12,957,931 

Total stockholders' equity

  12,523,159   13,111,030 

Total liabilities and stockholders' equity

 $17,306,077  $16,924,230  $16,699,939  $17,419,218 

 

See notes to condensed financial statements.  

1

Table of Contents

IKONICS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

  

Three Months Ended

  

Nine Months Ended

 
  September 30,  September 30, 
  

2018

  

2017

  

2018

  

2017

 
                 
NET SALES $4,651,358  $3,984,100  $13,357,013  $12,298,453 
                 
COST OF GOODS SOLD  3,124,539   2,660,149   8,805,460   8,441,010 
                 
GROSS PROFIT  1,526,819   1,323,951   4,551,553   3,857,443 
                 
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES  1,368,845   1,305,455   4,026,791   4,209,705 
                 
RESEARCH AND DEVELOPMENT EXPENSES  179,915   168,686   490,463   519,160 
                 
INCOME (LOSS) FROM OPERATIONS  (21,941)  (150,190)  34,299   (871,422)
                 

INTEREST EXPENSE

  (23,298)  (20,832)  (67,040)  (62,475)
                 
OTHER  13,760   6,309   34,986   17,364 
                 
INCOME (LOSS) BEFORE INCOME TAXES  (31,479)  (164,713)  2,245   (916,533)
                 
INCOME TAX EXPENSE (BENEFIT)  (6,727)  (53,760)  12,399   (321,617)
                 
NET LOSS $(24,752) $(110,953) $(10,154) $(594,916)
                 
LOSS PER COMMON SHARE:                
Basic $(0.01) $(0.06) $(0.01) $(0.30)
Diluted $(0.01) $(0.06) $(0.01) $(0.30)
                 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

                

Basic

  1,983,553   2,005,096   1,983,553   2,014,055 

Diluted

  1,983,553   2,005,096   1,983,553   2,014,055 

See notes to condensed financial statements.

2

Table of Contents

IKONICS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

  

Nine Months Ended

 
  

September 30,

 
  

2018

  

2017

 
         

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net loss

 $(10,154) $(594,916)

Adjustments to reconcile net loss to net cash provided by

        

Depreciation

  587,836   634,648 

Amortization

  27,463   28,724 

Stock based compensation

  10,054   17,527 

Net gain on sale and disposal of property, plant and equipment

     (32,635)

Deferred income taxes

  12,839    

Changes in working capital components:

        

Trade receivables

  214,519   692,269 

Inventories

  (184,825)  (560,137)

Prepaid expenses and other assets

  (42,328)  257,696 

Income tax receivable

  (8,092)  (261,614)

Accounts payable

  389,156   70,312 

Accrued expenses

  74,593   (104,254)

Net cash provided by operating activities

  1,071,061   147,620 
         

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchases of property, plant, and equipment

  (501,295)  (189,966)

Proceeds from sale of property and equipment

     32,635 

Purchases of intangible assets

  (36,289)  (32,420)

Purchases of short-term investments

  (4,145,000)  (1,915,000)

Proceeds on sale of short-term investments

  4,345,000   3,246,000 

Net cash provided by (used in) investing activities

  (337,584)  1,141,249 
         

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Payments on long-term debt

  (103,452)  (104,436)

Repurchase of common stock

     (233,787)

Proceeds from exercise of stock options

     1,885 

Net cash used in financing activities

  (103,452)  (336,338)
         

NET INCREASE IN CASH AND CASH EQUIVALENTS

  630,025   952,531 
         

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

  929,700   1,048,713 
         

CASH AND CASH EQUIVALENTS AT END OF PERIOD

 $1,559,725  $2,001,244 
         

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

        

Cash paid for interest

 $58,084  $53,574 

Cash paid for income taxes, net

 $7,652  $60,003 

See notes to condensed financial statements.

  

3

Table of Contents

 

IKONICS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

  

Three Months Ended

  

Six Months Ended

 
  

June 30,

  

June 30,

 
  

2019

  

2018

  

2019

  

2018

 
                 

NET SALES

 $4,596,411  $4,634,177  $8,125,102  $8,705,655 
                 

COST OF GOODS SOLD

  3,167,982   2,971,862   5,687,554   5,680,921 
                 

GROSS PROFIT

  1,428,429   1,662,315   2,437,548   3,024,734 
                 

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

  1,338,861   1,308,963   2,720,826   2,657,946 
                 

RESEARCH AND DEVELOPMENT EXPENSES

  270,465   156,472   449,307   310,548 
                 

(LOSS) INCOME FROM OPERATIONS

  (180,897)  196,880   (732,585)  56,240 
                 

INTEREST EXPENSE

  (22,515)  (23,807)  (44,790)  (43,742)
                 

OTHER

  17,303   11,805   33,497   21,226 
                 

(LOSS) INCOME BEFORE INCOME TAXES

  (186,109)  184,878   (743,878)  33,724 
                 

INCOME TAX (BENEFIT) EXPENSE

  (70,398)  39,542   (173,136)  19,126 
                 

NET (LOSS) INCOME

 $(115,711) $145,336  $(570,742) $14,598 
                 

(LOSS) INCOME PER COMMON SHARE

                

Basic

 $(0.06) $0.07  $(0.29) $0.01 

Diluted

 $(0.06) $0.07  $(0.29) $0.01 
                 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

                

Basic

  1,982,275   1,983,553   1,982,910   1,983,553 

Diluted

  1,982,275   1,983,553   1,982,910   1,983,553 

See notes to condensed financial statements.

4

Table of Contents

IKONICS CORPORATION

STATEMENTS OF STOCKHOLDERS’ EQUITY

THREE AND SIX MONTHS ENDED JUNE 30, 2019 and 2018 (unaudited)

For the three months ended June 30, 2019:

 

                 

Total

 
          

Additional

      

Stock-

 
  

Common Stock

  

Paid-in

  

Retained

  

holders’

 
  

Shares

  

Amount

  

Capital

  

Earnings

  

Equity

 
                     

BALANCE AT MARCH 31, 2019

  1,983,553  $198,355  $2,724,944  $9,734,620  $12,657,919 
                     

Net loss

           (115,711)  (115,711)
Common stock repurchased  (2,742)  (274)  (3,765)  (16,930)  (20,969)

Stock based compensation

        1,920      1,920 
                     

BALANCE AT JUNE 30, 2019

  1,980,811  $198,081  $2,723,099  $9,601,979  $12,523,159 

For the three months ended June 30, 2018:

                  

Total

 
          

Additional

      

Stock-

 
  

Common Stock

  

Paid-in

  

Retained

  

holders’

 
  

Shares

  

Amount

  

Capital

  

Earnings

  

Equity

 
                     

BALANCE AT MARCH 31, 2018

  1,983,553  $198,355  $2,712,283  $9,919,448  $12,830,086 
                     

Net income

           145,336   145,336 

Stock based compensation

        3,580      3,580 
                     

BALANCE AT JUNE 30, 2018

  1,983,553  $198,355  $2,715,863  $10,064,784  $12,979,002 

For the six months ended June 30, 2019:

                  

Total

 
          

Additional

      

Stock-

 
  

Common Stock

  

Paid-in

  

Retained

  

holders’

 
  

Shares

  

Amount

  

Capital

  

Earnings

  

Equity

 
                     

BALANCE AT DECEMBER 31, 2018

  1,983,553  $198,355  $2,723,024  $10,189,651  $13,111,030 
                     

Net loss

           (570,742)  (570,742)
Common stock repurchased  (2,742)  (274)  (3,765)  (16,930)  (20,969)

Stock based compensation

        3,840      3,840 
                     

BALANCE AT JUNE 30, 2019

  1,980,811  $198,081  $2,723,099  $9,601,979  $12,523,159 

For the six months ended June 30, 2018:

                  

Total

 
          

Additional

      

Stock-

 
  

Common Stock

  

Paid-in

  

Retained

  

holders’

 
  

Shares

  

Amount

  

Capital

  

Earnings

  

Equity

 
                     

BALANCE AT DECEMBER 31, 2017

  1,983,553  $198,355  $2,709,390  $10,050,186  $12,957,931 
                     

Net income

           14,598   14,598 

Stock based compensation

        6,473      6,473 
                     

BALANCE AT JUNE 30, 2018

  1,983,553  $198,355  $2,715,863  $10,064,784  $12,979,002 

5

Table of Contents

IKONICS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

  

Six Months Ended

 
  

June 30,

 
  

2019

  

2018

 

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net (loss) income

 $(570,742) $14,598 

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

        

Depreciation

  321,062   395,787 

Amortization

  24,308   18,615 

Stock based compensation

  3,840   6,473 

Net gain on sale and disposal of property and equipment

  (8,481)   

Deferred income taxes

     12,839 

Loss on intangible asset abandonment

  71,600    

Changes in working capital components:

        

Trade receivables

  (8,230)  321,347 

Inventories

  (465,661)  (385,481)

Prepaid expenses and other assets

  113,037   (16,184)

Income tax receivable

  (182,451)  (1,365)

Accounts payable

  (114,104)  508,323 

Accrued expenses

  46,897   2,962 

Net cash (used in) provided by operating activities

  (768,925)  877,914 
         

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchases of property and equipment

  (230,570)  (324,392)

Proceeds from sales of property and equipment

  15,596    

Purchases of intangibles assets

  (6,322)  (32,354)

Purchases of short-term investments

  (3,185,000)  (2,920,000)

Proceeds on sale of short-term investments

  2,940,000   2,895,000 

Net cash used in investing activities

  (466,296)  (381,746)
         

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Payment on long-term debt

  (69,761)  (70,040)

Repurchase of common stock

  (20,969)   

Net cash used in financing activities

  (90,730)  (70,040)
         

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

  (1,325,951)  426,128 
         

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

  1,623,137   929,700 
         

CASH AND CASH EQUIVALENTS AT END OF PERIOD

 $297,186  $1,355,828 
         

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

        

Cash paid for interest

 $39,812  $36,711 

Cash paid for income taxes, net

 $9,315  $7,652 

See notes to condensed financial statements.

6

Table of Contents

IKONICS CORPORATION

  

NOTES TO CONDENSED FINANCIAL STATEMENTS

  

(Unaudited)

  

 

1.

Basis of Presentation

  

The condensed balance sheet of IKONICS Corporation (the “Company”) as of SeptemberJune 30, 2018,2019, and the related condensed statements of operations for the three and ninesix months ended SeptemberJune 30, 2019 and 2018, the condensed statements of stockholders' equity for the three and six months ended June 30, 2019 and 2018, and 2017, andcondensed cash flows for the ninesix months ended SeptemberJune 30, 20182019 and 2017,2018, have been prepared without being audited.

  

In the opinion of management, these statements reflect all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of IKONICS Corporation as of SeptemberJune 30, 2018,2019, and the results of operations and cash flows for all periods presented.

  

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted.  Therefore, these statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.2018.

  

The results of operations for interim periods are not necessarily indicative of results that will be realized for the full fiscal year.

  

 

2.

Revenue

The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Topic 606. Revenue from Contracts with Customers (Topic 606), and in August 2015, FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date, which deferred the effective date of ASU 2014-09 by one year.  Topic 606 supersedes the revenue recognition requirements previously set forth in the Accounting Standards Codification (ASC) Topic 605, Revenue Recognition, and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services.

On January 1, 2018, the Company adopted Topic 606 for all customer contracts using the modified retrospective method.  The adoption of Topic 606 did not result in a change to revenue previously recognized under prior revenue recognition rules.  The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company does not expect the adoption of the new revenue standard to have a material impact to its operating results on an ongoing basis.  A majority of the Company’s sales revenue continues to be recognized when products are shipped from its manufacturing facility.  However, depending on the individual terms of the agreement with the customer, some sales revenue may be recognized when the goods arrive at the customer’s location, the point at which control transfers. 

Changes to the Company’s significant accounting policies as a result of adopting Topic 606 are discussed below:

Revenue recognition.  Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including noncash consideration, consideration paid or payable to customers and significant financing components.  While most of the Company’s revenue is contracted with customers through one-time purchase orders and short-term contracts, the Company does have long-term arrangements with certain customers. 

4

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. 

Individually promised goods and services in a contract are considered a distinct performance obligation and accounted for separately if the customer can benefit from the individual good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.  When an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price.  Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs are met. Costs of revenues consist primarily of direct labor, manufacturing overhead, materials and components.  The Company does not incur significant upfront costs to obtain a contract.  If costs to obtain a contract were to become material, the costs would be recorded as an asset and amortized to expense in a manner consistent with the related recognition of revenue.

The Company excludes government assessed and imposed taxes on revenue generating transactions that are invoiced to customers from revenue.  The Company includes freight billed to customers in revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.

The timing of revenue recognition, billings and cash collections results in accounts receivable on the balance sheet. 

Performance obligations.  A performance obligation is a promise in a contract to transfer a distinct good or service to the customer.  A contract’s transaction price is allocated to each distinct performance obligation in proportion to its standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.  The Company’s various performance obligations and the timing or method of revenue recognition are discussed below.

The Company sells its products to both distributors and end-users. Each unit of product delivered under a customer order represents a distinct and separate performance obligation as the customer can benefit from each unit on its own or with other resources that are readily available to the customer and each unit of product is separately identifiable from other products in the arrangement.

The transaction price for the Company’s products is the invoiced amount.  The Company does not have variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price.  The purchase order pricing in arrangements with customers is deemed to approximate standalone selling price; therefore, the Company does not need to allocate proceeds on a relative standalone selling price allocation between performance obligations.  The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.  There are no material obligations that extend beyond one year. 

Revenue is recognized when transfer of control occurs as defined by the terms in the customer agreement.  The Company immediately recognizes incidental items that are immaterial in the context of the contract.  The Company has applied the practical expedient in paragraph 606-10-25-16A and does not assess if immaterial items are promised goods or services.  The Company has also applied the practical expedient in paragraph 606-10-32-18 regarding the adjustment of the promised amount of consideration for the effects of a significant financing component when the customer pays for that good or service within one year or less, as the Company does not have any significant financing components in its customer arrangements as payment is received at or shortly after the point of sale, generally 30 to 90 days.

5

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

The Company estimates returns based on an analysis of historical experience if the right to return products is granted to its customers.  The Company does not record a return asset as non-conforming products are generally not returned.  The Company’s return policy does not vary by geography.  The customer has no rotation or price protection rights.

Trade receivables.  Trade receivables include amounts invoiced and currently due from customers. The amounts due are stated at their net estimated realizable value.  The Company records an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based on a review of all outstanding amounts on an on-going basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considers a customer’s financial condition, credit history, and current economic conditions. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received. Accounts are considered past due if payment is not received according to agreed-upon terms.

Sales commissions.  Sales commissions paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction.  The Company has elected to apply the practical expedient provided by ASC 340-40-25-4 and recognize the incremental costs of obtaining contracts as an expense when incurred, as the amortization period of the assets that would have otherwise been recognized is one year or less.  The Company records these costs in selling, general, and administrative expense.

Product warranties.   The Company offers warranties on various products and services. These warranties are assurance type warranties that are not sold on a standalone basis; therefore, they are not considered distinct performance obligations.  The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the revenue is recognized for the product sale. 

International revenue.  The Company markets its products to numerous countries in North America, Europe, Latin America, Asia and other parts of the world.  Foreign sales were approximately 29% of total sales during the first nine months of 2018 compared to 33% of sales for the first nine months of 2017.

3.

Short-Term Investments

  

The Company’s $2.7$2.9 million of short-term investments at SeptemberJune 30, 20182019 is comprised of eleven12 fully insured certificates of deposit with original maturities ofranging from five to six months and interest rates ranging from 1.80%2.25% to 2.05%.

6

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)2.40%

  

 

4.3.

Inventories

  

The major components of inventories are as follows:

  

 Sep 30, 2018  Dec 31, 2017  

Jun 30, 2019

  

Dec 31, 2018

 
                
Raw materials $1,644,515  $1,428,924  $1,794,771  $1,767,458 
Work-in-progress  375,122   423,186   449,081   370,075 
Finished goods  1,490,116   1,416,547   1,596,497   1,196,516 
Reduction to LIFO cost  (1,238,863)  (1,182,592)  (1,328,100)  (1,287,461)
                
Total Inventories $2,270,890  $2,086,065  $2,512,249  $2,046,588 

  

  

 

5.4.

Earnings Per Common Share (EPS)

  

Basic EPS is calculated using net lossincome (loss) divided by the weighted average of common shares outstanding.  Diluted EPS is similarcalculated similarly to Basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares that would have been outstanding if the potential dilutive common shares, such as those shares subject to options, had been issued.  The options disclosed in Note 5 have been excluded from the computation because of their antidilutive effect. 

 

Shares used in the calculation of diluted EPS are summarized below:

  

 

Three Months Ended

  

Three Months Ended

 
 Sep 30, 2018  Sep 30, 2017  

Jun 30, 2019

  

Jun 30, 2018

 
                

Weighted average common shares outstanding

  1,983,553   2,005,096   1,982,275   1,983,553 

Dilutive effect of stock options

            

Weighted average common and common equivalent shares outstanding

  1,983,553   2,005,096   1,982,275   1,983,553 

  

  

 

Nine Months Ended

  Six Months Ended 
 Sep 30, 2018  Sep 30, 2017  

Jun 30, 2019

  

Jun 30, 2018

 
                

Weighted average common shares outstanding

  1,983,553   2,014,055   1,982,910   1,983,553 

Dilutive effect of stock options

            

Weighted average common and common equivalent shares outstanding

  1,983,553   2,014,055   1,982,910   1,983,553 

 

If the Company was in a net income position for the three and ninesix months ended SeptemberJune 30, 2018,  5,0002019, all 16,000 options outstanding with a weighted average exercise price of $8.76 would have been included as part of the weighted average common and common equivalent shares outstanding as the options would have been dilutive while 13,000 options outstanding with a weighted average exercise price of $14.94 would have remained excluded as the options were anti-dilutive. 

If the Company was in a net income position for the three months ended September 30, 2017, all 18,168 options outstanding with a weighted average exercise price of $13.81$12.17 would have remained excluded from the computation of common share equivalents as the options were anti-dilutive.

 

IfFor the Company was in a net income position for the first ninethree and six months ended June 30, 2018, options to purchase all 18,000 shares of 2017, 2,250 options outstandingcommon stock with a weighted average exercise price of $8.91 would have been included as part$13.22 were outstanding but were excluded from the computation of the weighted average common and commonshares equivalent shares outstanding as the options would have been dilutive while 15,918 options outstanding with a weighted average exercise price of $14.51 would have remained excluded as the optionsbecause they were anti-dilutive.

 

7

Table of Contents

 

IKONICS CORPORATION

  

NOTES TO CONDENSED FINANCIAL STATEMENTS

  

(Unaudited)

  

 

6.5.

Stock-Based Compensation

  

The Company maintains a stock incentive2019 Equity Incentive Plan (the “2019 Plan”). The 2019 Plan replaced the 1995 Incentive Stock Option Plan (the "1995 Plan) upon its ratification by shareholders in April 2019.   The 1995 plan which authorizesauthorized the issuance of up to 442,750 shares of common stock.  Of those shares, 18,00016,000 were subject to outstanding options andas of June 30, 2019.  Awards granted under the 1995 Plan will remain in effect until they are exercised or expire according to their terms.    At the time the 2019 Plan was approved, there were 102,157 wereshares reserved for future grants under the 1995 Plan which will no longer be available for future grants.  

Under the terms of the 2019 Plan, the number of shares of common stock that may be the subject of awards and issued under the 2019 Plan was initially set at September102,157.  Subsequent to the approval of the 2019 Plan, 750 outstanding options granted under the 1995 were forfeited.  Under the terms of the 2019 Plan, those forfeited options are added back to the 2019 Plan reserve pool bringing the number of shares of common stock available for future awards under the 2019 Plan to 102,907.  As of June 30, 2018. The plan provides for granting eligible participants stock options or other stock2019 no awards as described byhave been granted under the plan, at option prices ranging from 85% to 110% of fair market value at the date of grant.  Options granted expire up to seven years after the date of grant.  Such options generally become exercisable over a one- to three-year period.2019 Plan.

 

The Company charged compensation cost of approximately $3,600$1,900 against income for the three months ended SeptemberJune 30, 20182019 and approximately $6,000$3,600 for the three months ended SeptemberJune 30, 2017.2018.  For the first ninesix months of 2018,2019, the Company charged compensation cost of approximately $10,100$3,800 and approximately $17,500$6,500 for the same period in 2017.2018.  As of SeptemberJune 30, 2018,2019, there was approximately $16,200$8,800 of unrecognized compensation cost related to unvested share-based compensation awards. That cost is expected to be recognized over the next three years.

  

The Company receives a tax deduction for certain stock option exercises during the period in which the options are exercised, generally for the excess of the market price at the time the stock options are exercised over the exercise price of the options.options, which increases additional paid in capital and reduces income taxes payable.

 

Proceeds from the exercise of 250 No stock options were approximately $2,000 forexercised during the ninesix months ended SeptemberJune 30, 2017.  2019  or June 30, 2018.

There were no options exercisedgranted during the ninesix months ended SeptemberJune 30, 2018.    

2019.  During the six months ended June 30, 2018, 2,750 options were granted.  The fair value of options granted during the ninesix months ended SeptemberJune 30, 2018 and 2017 was estimated using the Black-ScholesBlack Scholes option pricing model with the following assumptions:

 

  

2018

  

2017

 

Dividend yield

 0%  0% 

Expected volatility

 40.0%  41.3% 

Expected life of option (in years)

 5  5 

Risk-free interest rate

 2.8%  1.8% 

Fair value of each option on grant date

 $ 3.38  $ 3.43 

2018

Dividend yield

0

Expected volatility

40.0%
Expected life of option (years)5

Risk-free interest rate

2.8%

Fair value of each option on grant date

$3.38

 

There were 2,750 and 2,250 options granted

Stock option activity during each of the ninesix months ended SeptemberJune 30, 20182019 was as follows:

      

Weighted

 
      

Average

 
      

Exercise

 
  

Shares

  

Price

 

Outstanding at January 1, 2019

  18,000  $13.22 

Granted

      

Exercised

      

Expired and forfeited

  (2,000)  21.69 

Outstanding at June 30, 2019

  16,000  $12.17 

Exercisable at June 30, 2019

  13,415  $12.83 

The aggregate intrinsic value of all options outstanding and 2017, respectively while 2,918 options expired during the nine months ended Septemberexercisable at June 30, 2018.2019 was $0.

  

8

 

IKONICS CORPORATION

  

NOTES TO CONDENSED FINANCIAL STATEMENTS 

  

(Unaudited)

 

Stock option activity during the nine months ended September 30, 2018 was as follows:

      

Weighted

 
      

Average

 
      

Exercise

 
  

Shares

  

Price

 

Outstanding at January 1, 2018

  18,168  $13.81 

Granted

  2,750   8.63 

Exercised

      

Expired and forfeited

  (2,918)  12.56 
Outstanding at September 30, 2018  18,000   13.22 
Exercisable at September 30, 2018  12,247  $15.09 

The aggregate intrinsic value of all options outstanding and for those exercisable at September 30, 2018 was approximately $3,800 and $500, respectively.

 

7.6.

Segment Information

  

The Company’s reportable segments are strategic business units that offer different products and have varied customer bases.  There are fivefour reportable segments:  Domestic, Export,Chromaline, IKONICS Imaging, Digital Texturing (DTX) and Advanced Material Solutions (AMS).  DomesticChromaline sells screen printing film, emulsions, and inkjet receptive film primarily to distributors located in the United States and Canada.some end users.  IKONICS Imaging sells photo resistant film, art supplies, glass, metal medium and related abrasive etching equipment to both end user customers located in the United Statesusers and Canada.distributors.  AMS provides sound deadening and weight reduction technology to the aerospace industry along with products and services for etched composites, ceramics, glass and silicon wafers.  DTX includes products and customers related to patented and proprietary inkjet technology used for mold texturing and prototyping. Prior to 2019, the Company had one additional business segment called Export.  Export sellswas primarily the same products as Domesticresponsible for both Chromaline and the IKONICS Imaging sales outside of the United States and Canada.  Chromaline products not relatedsold within the United States and Canada prior to AMS2019 were included in a segment called Domestic.  To better reflect how the Company manages these businesses, beginning in 2019, the Export segment was eliminated.  Sales previously recorded in the Export segment are now included in either the Chromaline or DTX.IKONICS Imaging segments, respectively.  Both the 2019 and 2018 financial information reflect the new reportable segments.   The accounting policies applied to determine the segment information are the same as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.2018.

  

Management evaluates the performance of each segment based on the components of divisional income (loss).  Assets and liabilities are not allocated to segments, except for trade receivables which are allocated based on the previous segmentation.  Financial information with respect to the reportable segments follows:

  

For the three months ended SeptemberJune 30, 2019:

  

IKONICS

 
      

IKONICS

                 
  

Chromaline

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 

Net sales

 $3,107,116  $958,128  $112,601  $418,566  $  $4,596,411 

Cost of goods sold

  2,280,224   501,006   51,547   335,205      3,167,982 

Gross profit

  826,892   457,122   61,054   83,361      1,428,429 

Selling general and administrative*

  467,091   248,050   34,761   88,362   500,597   1,338,861 

Research and development*

              270,465   270,465 

Income (loss) from operations

 $359,801  $209,072  $26,293  $(5,001) $(771,062) $(180,897)

For the three months ended June 30, 2018: 

  

IKONICS

 
      

IKONICS

                 
  

Chromaline

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 

Net sales

 $3,099,892  $968,933  $94,322  $471,030  $  $4,634,177 

Cost of goods sold

  2,037,949   509,613   33,612   390,688      2,971,862 

Gross profit

  1,061,943   459,320   60,710   80,342      1,662,315 

Selling general and administrative*

  441,393   244,633   32,596   97,477   492,864   1,308,963 

Research and development*

              156,472   156,472 

Income (loss) from operations

 $620,550  $214,687  $28,114  $(17,135) $(649,336) $196,880 

 

For the six months ended June 30, 2019:

 

IKONICS

  

IKONICS

 
         

IKONICS

                      

IKONICS

                 
 

Domestic

  

Export

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

  

Chromaline

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 
Net sales $1,893,513  $1,320,594  $810,240  $158,862  $468,149  $  $4,651,358  $5,136,457  $2,046,934  $205,361  $736,350  $  $8,125,102 
Cost of goods sold  1,151,121   1,055,901   466,763   30,279   420,475      3,124,539   3,833,834   1,086,510   85,593   681,617      5,687,554 
Gross profit  742,392   264,693   343,477   128,583   47,674      1,526,819   1,302,623   960,424   119,768   54,733      2,437,548 
Selling, general and administrative*  346,137   127,647   256,094   42,922   91,876   504,169   1,368,845 

Selling general and administrative*

  912,094   570,503   69,366   176,510   992,353   2,720,826 
Research and development*  -   -   -   -   -   179,915   179,915               449,307   449,307 
Income (loss) from operations $396,255  $137,046  $87,383  $85,661  $(44,202) $(684,084) $(21,941) $390,529  $389,921  $50,402  $(121,777) $(1,441,660) $(732,585)

For the six months ended June 30, 2018:

  

IKONICS

 
      

IKONICS

                 
  

Chromaline

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 

Net sales

 $5,440,702  $2,188,281  $182,988  $893,684  $  $8,705,655 

Cost of goods sold

  3,702,827   1,133,224   59,004   785,866      5,680,921 

Gross profit

  1,737,875   1,055,057   123,984   107,818      3,024,734 

Selling general and administrative*

  866,722   529,658   67,448   182,260   1,011,858   2,657,946 

Research and development*

              310,548   310,548 

Income (loss) from operations

 $871,153  $525,399  $56,536  $(74,442) $(1,322,406) $56,240 


*The Company does not allocate all selling, general and administrative expenses or any research and development expenses to its operating segments for internal reporting.

 

9

Table of Contents

 

IKONICS CORPORATION

  

NOTES TO CONDENSED FINANCIAL STATEMENTS 

  

(Unaudited)

  

For the three months ended September 30, 2017:

  

IKONICS

 
          

IKONICS

                 
  

Domestic

  

Export

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 

Net sales

 $1,790,331  $1,083,594  $731,289  $121,255  $257,631  $  $3,984,100 

Cost of goods sold

  1,026,311   819,728   417,882   59,293   336,935      2,660,149 

Gross profit (loss)

  764,020   263,866   313,407   61,962   (79,304)     1,323,951 

Selling, general and administrative*

  315,941   131,100   287,087   44,805   91,442   435,080   1,305,455 

Research and development*

  -   -   -   -   -   168,686   168,686 

Income (loss) from operations

 $448,079  $132,766  $26,320  $17,157  $(170,746) $(603,766) $(150,190)

For the nine months ended September 30, 2018:

  

IKONICS

 
          

IKONICS

                 
  

Domestic

  

Export

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 

Net sales

 $5,229,971  $3,686,815  $2,736,544  $341,850  $1,361,833  $  $13,357,013 

Cost of goods sold

  3,137,858   2,904,558   1,467,420   89,283   1,206,341      8,805,460 

Gross profit

  2,092,113   782,257   1,269,124   252,567   155,492      4,551,553 

Selling, general and administrative*

  965,754   388,205   772,299   110,370   274,136   1,516,027   4,026,791 

Research and development*

  -   -   -   -   -   490,463   490,463 

Income (loss) from operations

 $1,126,359  $394,052  $496,825  $142,197  $(118,644) $(2,006,490) $34,299 

For the nine months ended September 30, 2017:

  

IKONICS

 
          

IKONICS

                 
  

Domestic

  

Export

  

Imaging

  

DTX

  

AMS

  

Unalloc.

  

Total

 
Net sales $4,910,856  $3,510,691  $2,664,330  $707,730  $504,846  $  $12,298,453 
Cost of goods sold  2,887,111   2,755,371   1,394,675   453,712   950,141      8,441,010 
Gross profit (loss)  2,023,745   755,320   1,269,655   254,018   (445,295)     3,857,443 
Selling, general and administrative*  1,001,434   516,958   824,692   130,301   292,562   1,443,758   4,209,705 
Research and development*  -   -   -   -   -   519,160   519,160 
Income (loss) from operations $1,022,311  $238,362  $444,963  $123,717  $(737,857) $(1,962,918) $(871,422)


*

The Company does not allocate all general and administrative expenses or any research and development expenses to its operating segments for internal reporting.

Trade receivables by segment as of SeptemberJune 30, 20182019 and December 31, 20172018 were as follows:

  

 Sep 30, 2018  Dec 31, 2017  

Jun 30, 2019

  

Dec 31, 2018

 
                
Domestic $928,122  $1,119,228 
Export  460,788   558,872 

Chromaline

 $1,568,512  $1,550,411 
IKONICS Imaging  243,912   238,813   323,741   360,551 
DTX  7,162   64,278   26,559   15,692 
AMS  356,295   238,848   298,714   331,708 
Unallocated  (20,538)  (29,779)  5,919   (43,147)
                
Total $1,975,741  $2,190,260  $2,223,445  $2,215,215 

  

10

Table of Contents

IKONICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

  

 

8.7.

Income Taxes

  

The Company recorded its interim provision for income taxes by applying the estimated annual effective tax rate to the year-to-date pre-tax income (loss) and adjusting for discrete tax items recorded in the period. Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax reporting purposes, including for depreciation, amortization, and vacation accruals, and deductions related to allowances for doubtful accounts receivable and inventory reserves. The provision for income taxes (benefits) included current federal and state income tax expense (benefit), as well as deferred federal and state income tax expense.

The effective tax rate for the three months ended June 30, 2019 is a benefit of 37.8%, compared to expense of 21.4% for the three months ended June 30, 2018. The primary driver of the increase in the effective tax rate is the quarterly loss as compared to income for the same period last year. The Company recorded an income tax benefit of $70,000 and an income tax expense of $40,000 for the three months ended June 30, 2019 and 2018, respectively.

The effective tax rate for the six months ended June 30, 2019 is a benefit of 23.3%, compared to expense of 56.7% for the six months ended June 30, 2018. The primary driver of the decrease in our effective tax rate is the year-to-date loss as compared to income for the same period last year. We recorded an income tax benefit of $173,000 and an income tax expense of $19,000 for the six months ended June 30, 2019 and 2018, respectively. 

The income tax provision for the 2019 and 2018 periods differ from the expected tax benefit due to unfavorable non-deductible items and generation of research and development credits.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority is more-likely-than-not to sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the condensed consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. As of June 30, 2019 the Company has no unrecognized tax benefits.

The Company is not currently under examination in any jurisdiction. In the event of any future tax assessments, the Company has elected to record the income taxes and any related interest and penalties as income tax expense on the statement of operations.  The federal Tax Cut and Jobs Act of 2017 (the “Tax Reform Act”) was enacted December 22, 2017.  Effective January 1, 2018, the Tax Reform Act reduced statutory corporate income tax rates from 35% to 21% in addition to other tax changes including re-valuation of deferred tax assets and liabilities as of December 31, 2017.  

For the first nine months of 2018, the Company realized an income tax expense of $12,000, which reflects the new federal corporate rate of 21% versus the income tax benefit of $322,000 or an effective rate of 35.1%, for the first nine months of 2017.  The Company’s effective rate for 2018 relates to the higher year-to-date pre-tax income generated and the related impact of discrete events and non-deductible permanent items.  The 2017 tax benefit for the first nine months was due to the year-to-date net loss. The income tax provision for the 2018 and 2017 periods differ from the expected benefit due to credits for research and development and other non-deductible items.

The Company’s federal net operating loss carryforward and research and development credit carryover as of September 30, 2018 was $141,000 and $27,000, respectively, and will begin to expire in 2037.  The Company’s gross state net operating loss carryforwards and research and development credit carryover as of September 30, 2018 was $61,000 and $115,000, respectively and begin to expire in 2026. 

The valuation allowance balance of $91,000 at September 30, 2018, relates entirely to Minnesota research and development credit carryforwards that the Company does not expect to utilize and begin to expire in 2028. 

It has been the Company’s policy to recognize interest and penalties related to uncertain tax positions in income tax expense.  As of September 30, 2018 and December 31, 2017, there was no liability for unrecognized tax benefits.

The Company is subject to federal and state taxation. As of September 30, 2018, with few exceptions, the Company is no longer subject to examination prior to tax year 2014. 

changes.  

 

1110

 

 

IKONICS CORPORATION

  

The information presented below in Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended.  Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. These forward-looking statements include statements relating to our future plans and objectives and results. Such statements are subject to risks and uncertainties, including those discussed elsewhere in this report and under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017,2018, as updated in our subsequent reports filed with the SEC, which could cause actual results to differ materially from those projected.  Because actual results may differ, readers are cautioned not to place undue reliance on these forward-looking statements.

  

ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

The following management’s discussion and analysis focuses on those factors that had a material effect on the Company’s financial results of operations during the thirdsecond quarter of 20182019 and first ninesix months of 2018,2019, as well as the same periods of 2017.2018.  It should be read in connection with the Company’s condensed unaudited financial statements and notes thereto included in this Form 10-Q.

  

Critical Accounting Estimates 

  

The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America.  Therefore, the Company is required to make certain estimates, judgments and assumptions that the Company believes are reasonable based upon the information available.  These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented.  The accounting estimates, which IKONICS believes are the most critical to aid in fully understanding and evaluating its reported financial results, include the following:

  

Trade Receivables.  The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by review of the current credit information.  The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified.  While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same collection history that has occurred in the past.  The general payment terms are net 30-45 days for domestic customers and net 30-90 days for foreign customers.  A small percentage of the trade receivables balance is denominated in a foreign currency with no concentration in any given country.  At the end of each reporting period, the Company analyzes the receivable balance for customers paying in a foreign currency.  These balances are adjusted to each quarter or year-end spot rate in accordance with FASB ASC 830, Foreign Currency Matters.  The Company also maintains a provision for any customer related returns based upon historical experience of actual returns and any specifically identified product issues, refunds or credits.

  

Inventories.  Inventories are valued at the lower of cost or marketnet realizable value using the last in, first out (LIFO) method.  The Company monitors its inventory for obsolescence and records reductions from cost when required.

  

Income Taxes.  Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.  Deferred tax assets and liabilities are presented as long-term on a net basis.  The Company follows the accounting standard on accounting for uncertainty in income taxes, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.  Under this guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement.  The guidance on accounting for uncertainty in income taxes also addresses derecognition, classification, interest and penalties on income taxes, and accounting in interim periods.

 

12

Table of Contents

Revenue.  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Topic 606. Revenue from Contracts with Customers (Topic 606), and in August 2015, FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date, which deferred the effective date of ASU 2014-09 by one year.  Topic 606 supersedes the revenue recognition requirements previously set forth in the Accounting Standards Codification (ASC) Topic 605, Revenue Recognition, and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services.

On January 1, 2018, the Company adopted Topic 606 for all customer contracts using the modified retrospective method.  The adoption of Topic 606 did not result in a change to revenue previously recognized under prior revenue recognition rules.  The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company does not expect the adoption of the new revenue standard to have a material impact to its operating results on an ongoing basis.  A majority of the Company’s sales revenue continues to be recognized when products are shipped from its manufacturing facility.  However, depending on the individual terms of the agreement with the customer, some sales revenue may be recognized when the goods arrive at the customer’s location, the point at which control transfers. 

Changes to the Company’s significant accounting policies as a result of adopting Topic 606 are discussed below:

Revenue recognition.  Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including noncash consideration, consideration paid or payable to customers and significant financing components.  While most of the Company’s revenue is contracted with customers through one-time purchase orders and short-term contracts, the Company does have long-term arrangements with certain customers.  Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. 

  

Individually promised goods and services in a contract are considered a distinct performance obligation and accounted for separately if the customer can benefit from the individual good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.  When an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price.  Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs are met. Costs of revenues consist primarily of direct labor, manufacturing overhead, materials and components.  The Company does not incur significant upfront costs to obtain a contract.  If costs to obtain a contract were to become material, the costs would be recorded as an asset and amortized to expense in a manner consistent with the related recognition of revenue.

  

11

Table of Contents

The Company excludes governmental assessed and imposed taxes on revenue transactions that are invoiced to customers from revenue.  The Company includes freight billed to customers in revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.

  

The timing of revenue recognition, billings and cash collections results in accounts receivable on the balance sheet.

13

Table of Contents

  

Performance obligations.  A performance obligation is a promise in a contract to transfer a distinct good or service to the customer.  A contract’s transaction price is allocated to each distinct performance obligation in proportion to its standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.  The Company’s various performance obligations and the timing or method of revenue recognition are discussed below.below: 

  

The Company sells its products to both distributors and end-users. Each unit of product delivered under a customer order represents a distinct and separate performance obligation as the customer can benefit from each unit on its own or with other resources that are readily available to the customer and each unit of product is separately identifiable from other products in the arrangement.

  

The transaction price for the Company’s products is the invoiced amount.  The Company does not have variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price.  The purchase order pricing in arrangements with customers is deemed to approximate standalone selling price; therefore, the Company does not need to allocate proceeds on a relative standalone selling price allocation between performance obligations.  The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. There are no material obligations that extend beyond one year. 

  

Revenue is recognized when transfer of control occurs as defined by the terms in the customer agreement. The Company immediately recognizes incidental items that are immaterial in the context of the contract.  The Company has also applied the practical expedient in paragraph 606-10-32-18 regarding the adjustment of the promised amount of consideration for the effects of a significant financing component when the customer pays for that good or service within one year or less, as the Company does not have any significant financing components in its customer arrangements as payment is received at or shortly after the point of sale, generally 30thirty to 90ninety days.

  

The Company estimates returns based on an analysis of historical experience if the right to return products is granted to its customers.  The Company does not record a return asset as non-conforming products are generally not returned.  The Company’s return policy does not vary by geography.  The customer has no rotation or price protection rights.rights, and the Company is not under a warranty obligation.

  

Trade receivables.  Trade receivables include amounts invoiced and currently due from customers. The amounts due are stated at their net estimated realizable value.  The Company records an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based on a review of all outstanding amounts on an on-going basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considers a customer’s financial condition, credit history, and current economic conditions. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received. Accounts are considered past due if payment is not received according to agreed-upon terms.

  

Sales commissions.  Sales commissions paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction.  The Company has elected to apply the practical expedient provided by ASC 340-40-25-4 and recognize the incremental costs of obtaining contracts as an expense when incurred, as the amortization period of the assets that would have otherwise been recognized is one year or less.  The Company records these costs in selling, general, and administrative expense.

  

Product warranties.warranty.   The Company offers warranties on various products and services. These warranties are assurance type warranties that are not sold on a standalone basis; therefore, they are not considered distinct performance obligations.  The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the revenue is recognized for the product sale. 

  

International revenue.  The Company markets its products to numerous countries in North America, Europe, Latin America, Asia and other parts of the world.  Foreign sales were approximately 29% of total sales during the first ninesix months of 20182019 compared to 33% of sales28% for the first ninesix months of 2017. 2018.

14

Table of Contents

 

Results of Operations 

  

Quarter Ended SeptemberJune 30, 20182019 Compared to Quarter Ended SeptemberJune 30, 20172018

  

Sales.  Sales increased 16.7% duringThe Company’s 2019 second quarter sales of $4.6 million were $38,000, or 0.8%, lower than the third2018 second quarter sales of $4.6 million.  AMS second quarter 2019 sales of $419,000 decreased by 11.1% from second quarter 2018 sales of $471,000 due to lower sales to its two largest customers.  2019 second quarter IKONICS Imaging sales of $958,000 were $11,000, or 1.1%, lower than the sales for the same period in 2018 as equipment sales continue to lag behind 2018.  Partially offsetting these sales decreases, DTX had improved film sales, increasing from $94,000 in the second quarter of 2018 to record third$113,000 in the second quarter of 2019, a 19.4% increase.  Chromaline sales for the second quarter of $4.7 million, compared2019 were similar to $4.0 million during the same period in 2017.  Third quarter sales were favorably impacted by AMS sales which grew by $211,000, or 81.7% from $258,000 during the third quarterlast year at $3.1 million.    

12

Table of 2017 to $468,000 in the third quarter of 2018.  Most of this increase is related to increased sales to AMS’s largest customer who is expected to maintain similar sales levels for the remainder of 2018.  Export sales also realized a 21.9% sales increase in the third quarter as sales increased from $1.1 million in 2017 to $1.3 million in 2018, mainly due to higher sales into Asia which is partially timing related.  IKONICS Imaging sales increased from $731,000 in the third quarter of 2017 to $810,000 in the third quarter of 2018, a 10.8% increase.  IKONICS Imaging sales for the third quarter of 2018 benefitted from both improved film and equipment sales.  DTX sales were favorably impacted by a $78,000 film shipment which occurs approximately every other year as DTX 2018 third quarter sales of $159,000 were $38,000, or 31.0%, higher than the same period in 2017.  Domestic sales grew from $1.8 million in third quarter of 2017 to $1.9 million in the third quarter of 2018, a 5.8% increase.

Contents

 

Gross Profit.  Gross profit was $1.5$1.4 million, or 32.8%31.1% of sales, in the thirdsecond quarter of 20182019 compared to $1.3$1.7 million, or 33.2%35.9% of sales, for the same period in 2017.2018.  The 2018 third quarterChromaline gross margin decrease from 34.3% in the second quarter of 2018 to 26.6% for the second quarter of 2019 was negativelydue to a less favorable sales mix as an increase in lower margin sales into Asia were offset by a decrease in higher margin domestic sales.  An increase in certain raw material pricing also unfavorably impacted the gross margin for some Chromaline emulsion products.  The DTX gross margin for the second quarter of 2019 was also lower at 54.2% compared to 64.4% for the same period in 2018.  Despite lower sales volumes, the AMS gross margin improved to 19.9% in the second quarter of 2019, up from 17.1% in the second quarter of 2018 as a result of lower costs in 2019.  The IKONICS Imaging 2019 second quarter margin of 47.7% was similar to the second quarter 2018 gross margin of 47.4%

Selling, General and Administrative Expenses.  Selling, general and administrative expenses were $1.3 million, or 29.1% of sales, in the second quarter of 2019 compared to $1.3 million, or 28.2% of sales, for the same period in 2018.  Selling, general and administrative expenses for the second quarter of 2019 increased primarily due to higher medical insurance expenses.

Research and Development Expenses.  Research and development expenses during the second quarter of 2019 were $270,000, or 5.9% of sales, versus $156,000, or 3.4%, of sales for the same period in 2018.  The 2019 second quarter increase is related to additional research and development staffing expenses.  Additionally, legal and patent expenses in the second quarter of 2019 increased due to the write off of patent application costs of $72,000 that were previously recorded as an asset, as the Company determined that it would no longer continue to pursue those patent applications.

Interest Expense.  Interest expense for the second quarter of 2019 was $23,000 compared to interest expense of $24,000 during the second quarter of 2018.  

Income Taxes.  For the second quarter of 2019, the Company realized an income tax benefit of $70,000, or an effective rate of 37.8%, compared to expense of $40,000, or an effective tax of 21.4% for the three months ended June 30, 2018.  The primary driver of the change in the Company's effective tax rate is the quarterly loss as compared to income for the same period last year.  The income tax provision for the 2019 and 2018 periods differ from the expected tax benefit due to unfavorable non-deductible items and generation of research and development tax credits.

Six Months Ended June 30, 2019 Compared to Six Months Ended June 30, 2018

Sales.  The Company’s 2019 first half sales of $8.1 million were 6.7% lower than the 2018 first half sales of $8.7 million.  Chromaline sales for the first six months of 2019 decreased by $304,000, or 5.6%, compared to the same period last year.  Chromaline 2019 first half sales were adversely affected by cold weather shipping constraints in the first quarter since its emulsion products are not freeze-thaw stable.  AMS sales for the first six months of 2019 decreased from $894,000 during the same period in 2018 to $736,000, a 17.6% decrease resulting from a decrease in sales to its two largest customers.  IKONICS Imaging sales for the first six months of 2019 were $2.0 million, $141,000, or 6.5%, lower than the sales for the first half of 2018 mainly due to lower equipment and film sales.    Partially offsetting these sales decreases, DTX sales increased from $183,000 in the first half of 2018 to $205,000 in the first half of 2019, a 12.2% increase resulting from increased film sales.  

Gross Profit.  Gross profit was $2.4 million, or 30.0% of sales, in the first half of 2019 compared to $3.0 million, or 34.7% of sales, for the same period in 2018. The Chromaline gross margin decreased from 31.9% in the first half of 2018 to 25.4% for the first six months of 2019 due to a decrease in higher margins sales in the United States which were partially offset by an increase in lower margin Export sales into AsiaAsia.  The Chromaline gross margin in the first half of 2019 was also unfavorably impacted by an increase in certain raw material pricing for some emulsion products along with 2018 third quarter production cost increases.  The 2018 third quarter margin decrease was partially offset  by increased AMShigher manufacturing costs.  Lower sales volumes asnegatively impacted the 2019 first half AMS gross margin improvedwhich decreased from a negative 30.8%12.1% in third quarterfirst half of 20172018 to a positive 10.2% in7.4% for the third quarterfirst six months of 2018.2019.  A large portion of the AMS cost structure is fixed, causing sales volumes to have a significant impact on its gross margin.  The 2019 AMS margin decrease due to lower sales volumes was partially mitigated by overall lower costs in 2019.  For the first six months of 2019, the IKONICS Imaging gross margin was 46.9% compared to 48.2% for the same period in 2018 third quarterwhile the DTX gross margin also improved overfor the first six months of 2019 was 58.3% versus 67.8% for the same period last year due an increase in higher margin film shipments.

year.

Selling, General and Administrative Expenses.  Selling, general and administrative expenses were $1.4$2.7 million, or 29.4%33.5% of sales, in the third quarterfirst half of 20182019 compared to $1.3$2.7 million, or 32.8%30.5% of sales, for the same period in 2017.  The third quarter 2018 increase in selling,2018.  Selling, general and administrative expense is primarily related to higher health insurance expenses partially offset by lower promotional and travel expenses. 

Research and Development Expenses.  Research and development expenses during the third quarter of 2018 were $180,000, or 3.9% of sales, versus $169,000, or 4.2% of sales, for the same period in 2017.  The increase in 2018 third quarter costs isfirst six months of 2019 increased primarily due to higher health insurance expenses.  

Interest Expense.  Interest expense forcosts.   Additionally, the third quarter of 2018 was $23,000 compared to interest expense of $21,000 during the third quarter of 2017.  The interest expense is related to a $3.4 million financing agreement the Company entered into during 2016 to finance the construction of a 27,300-square foot building and related equipment for useincrease in the Company’s manufacturepercentage of sound deadening technology usedexpense as it relates to sales increased in the aerospace industry and products consisting of etched composites, ceramics, glass and silicon wafers.

Income Taxes. For the third quarter of2019 versus 2018 the Company realized an income tax benefit of $7,000, or an effective rate of 21.4% which reflects the new federal rate of 21% enacted December 22, 2017 through the Tax Cut and Jobs Act, compared to the income tax benefit of $54,000, or an effective rate of 32.6%, for the same period in 2017.  The decrease in the quarterly effective tax rate for 2018 over 2017 is primarily due to the lower federal tax rate.  The income tax provision for the 2018 and 2017 periods differ from expected tax benefit due to unfavorable non-deductible items offset by the generation of research and development tax credits.

15

Table of Contents

Nine Months Ended September 30, 2018 Compared to the Nine Months Ended September 30, 2017

Sales.  Sales increased 8.6% during the first nine months of 2018 to $13.4 million compared to $12.3 million during the same period in 2017.  AMS sales for the first ninesix months of 2018 increased by $857,000, or 169.8%, compared to the same period last year, as the Company realized increased sales from its largest customer.  The customer maintained expected activity level for the entire 2018 period while AMS sales during the first nine months of 2017 were unfavorably affected by a temporary decrease in orders from its largest customer.  Domestic sales also increased from $4.9 million in the first nine months of 2017 to $5.2 million in the first nine months of 2018, a $319,000, or 6.5%, sales increase due to improved emulsion and film sales, while Export sales for the first nine month of 2018 increased by $176,000, or 5.0%,  due to higher sales to both the Middle East and Latin America.  Equipment sales increases resulted in IKONICS Imaging sales growing $72,000, or 2.7% in the first nine months of 2018 compared to the same period in 2017.  Sales for the first nine months  of 2018 were unfavorably impacted by a $366,000, or 51.7%, DTX sales decrease as 2017 DTX sales benefitted from $320,000 in sales of two DTX printers.  There were no printer sales during the first nine months of 2018, and the Company does not anticipate any new DTX printer sales until 2019.

Gross Profit.  Gross profit was $4.6 million, or 34.1% oflower sales in the first nine months of 2018 compared to $3.9 million, or 31.4% of sales, for the same period in 2017. AMS increased sales volumes benefitted the 2018 gross margin, as the AMS gross margin improved from a negative 88.2% in first nine months of 2017 to a positive 11.4% in 2018.  A large portion of the AMS cost structure is fixed, causing sales volumes to have a significant impact on its gross margin.  The 2018 DTX gross margin improved to 73.9% from 35.9% in the first nine months of 2017, as the 2017 gross margin was negatively affected by the sale of two low margin printers.  The IKONICS Imaging,  Domestic, and Export gross margins were negatively affected by higher production costs  for the first nine months of 2018 compared to the same period last year.2019.

Selling, General and Administrative Expenses.  Selling, general and administrative expenses were $4.0 million, or 30.1% of sales, in the first nine months of 2018 compared to $4.2 million, or 34.2% of sales, for the same period in 2017.  The 2018 decrease in selling, general and administrative expense is related to the Company’s cost reduction initiative.  The Company realized lower travel, promotional, consulting and salary expenses which were partially offset by higher health insurance expenses.

Research and Development Expenses.  Research and development expenses during the first ninesix months of 20182019 were $490,000,$449,000, or 3.7%5.5% of sales, versus $519,000,$311,000, or 4.2%3.6%, of sales for the same period in 2017.2018.  The decreaseincrease for the first half of 2019 is related to additional research and development staffing expenses.  Additionally, legal and patent expenses in 2018 costs isthe first half of 2019 increased due to lower production trial expenses.  Thethe write off of patent application costs that were previously recorded as an asset as the Company incurred additional production trial expenses in 2017 relateddetermined that it would no longer continue to the development of its new SubTHAT! film product.

pursue those patent applications.

 

Interest Expense.  Interest expense for the first ninesix months of 20182019 was $67,000$45,000 compared to interest expense of $62,000$44,000 during the first ninesix months of 2017.  The interest expense is related to a $3.4 million financing agreement the Company entered into during 2016 to finance the construction of a 27,300-square foot building as well as related equipment for use in the Company’s manufacture of sound deadening technology used in the aerospace industry and products consisting of etched composites, ceramics, glass and silicon wafers.

2018.  

 

Income Taxes.  
For the first ninesix months of 2018,2019, the Company realized an income tax expensebenefit of $12,000,$173,000, or an effective rate of 552.3% which reflects the new federal corporate rate23.3%, compared to expense of 21% versus the income tax benefit of $322,000$19,000, or an effective ratetax of 35.1%,56.7% for the first ninesix months ended June 30, 2018.  The primary driver of 2017. The Company’s increasedthe decrease in our effective tax rate for 2018 relates to the higher year-to-date pre-tax income generated and the related impact of discrete events and non-deductible permanent items.  The 2017 year-to-date third quarter tax benefit was due tois the year-to-date net loss.loss as compared to income for the same period last year.  The income tax provision for the 20182019 and 20172018 periods differ from the expected tax benefit due to credits forunfavorable non-deductible items and generation of research and development and other non-deductible items

tax credits.
16

 

Liquidity and Capital Resources 

  

Outside of the building expansion, for which $3.4 million in financing was obtained during 2016, the Company has financed its operations principally with funds generated from operations.  These funds have been sufficient to cover the Company’s normal operating expenditures, annual capital requirements, and research and development expenditures.

  

13

Cash and cash equivalents were $297,000 and $1.6 million and $930,000 at SeptemberJune 30, 20182019 and December 31, 2017,2018, respectively.  Operating activities provided $1.1 millionused $769,000 in cash during the first ninesix months of 20182019 compared to $148,000providing $878,000 of cash provided byused in operating activities during the same period in 2017.2018.  Cash provided by (used in) operating activities is primarily the result of net income or loss(losses) adjusted for non-cash depreciation, amortization, and certain changes in working capital components discussed in the following paragraph.

 

During the first ninesix months of 2019, trade receivables increased $8,000.  The Company believes that the quality of its receivables is high and that strong internal controls are in place to maintain proper collections.  Inventories increased by $466,000 due to higher finished goods and raw material levels as the Company is ramping up inventory levels to meet demand for the remainder of 2019 in addition to lower than expected sales for the first half of 2019.  Prepaid expenses and other assets decreased by $113,000, reflecting a decrease in a receivable related to the reimbursement of 2018 medical insurance costs that the Company received from its stop-loss insurance carrier.   Accounts payable decreased by $114,000 due to the timing of vendor payments.  Accrued expenses increased by $47,000, reflecting the timing of compensation payments while income taxes receivable increased by $182,000 due to the recognition of the 2019 first six month tax benefit.

During the first six months of 2018, the timing of collections resulted in a $215,000$321,000 decrease in trade receivables.  The Company believes that the quality of its receivables is high and that strong internal controls are in place to maintain proper collections.  Inventories increased by $185,000$385,000 due to higher raw material and finished goods levels as the Company is increasing inventory levels to meet expected fourth quarter sales demand.levels.  Prepaid expenses and other assets increased by $42,000,$16,000, reflecting prepayments on annual software license agreements.inventory items which were not received by the Company until the third quarter of 2018.  Accounts payable increased by $389,000$508,000 due to the timing of vendor payments for recent large raw materials purchases.  Accrued expenses increased by $75,000,$3,000, reflecting an increase in the accrual for health insurance coststiming of compensation payments while income taxes receivable increased by $8,000$1,000 due to the timing of estimated tax payments compared to the calculated 2018 tax liability.

 

During the first ninesix months of 2017, the timing of collections resulted in a $692,000 decrease in trade receivables.  The Company believes that the quality of its receivables is high and that strong internal controls are in place to maintain proper collections.  Inventories increased by $560,000 due to higher raw material and finished goods levels.  Prepaid expenses and other assets decreased $258,000.  The prepaid expense balance at December 31, 2016 included prepayments related to two DTX printers which were sold in 2017.  Accounts payable increased $70,000 due to the timing of vendor payments mainly related to raw material purchases.  Accrued expenses decreased $104,000, reflecting the timing of compensation payments while income taxes receivable increased $262,000 due to the timing of estimated tax payments compared to the calculated 2017 tax liability.

During the first nine months of 2018,2019, cash used in investing activities was $338,000.  Eighteen$466,000.  Twelve certificates of deposits totaling $4.3$2.9 million matured during the first ninesix months of 2018.2019.  The Company purchased seventeenthirteen certificates of deposits totaling $4.1$3.2 million.  The Company’s purchases of property and equipment of $501,000$231,000 were mainly for building upgrades and improvements to production and process capabilities.capabilities and to replace two vehicles.  The Company received $16,000 in proceeds from the sale of two vehicles and equipment.  Also, during the first ninesix months of 2018,2019, the Company incurred $36,000$6,000 in patent application costs that the Company records as an asset and amortizes upon successful completion of the application process.

  

During the first ninesix months of 2017,2018, cash provided byused in investing activities was $1.1 million.  The Company obtained proceeds from 14$382,000.  Twelve certificates of deposits totaling $3.2$2.9 million andmatured during the first six months of 2018.  The Company purchased eighttwelve certificates of deposits totaling $1.9$2.9 million.  The Company’s purchases of property and equipment of $190,000$324,000 were mainly for building upgrades and improvements to production and process capabilities and two vehicles.capabilities. Also, during the first ninesix months of 2017,2018, the Company incurred $32,000 in patent application costs that the Company has recordedrecords as an asset and will amortizeamortizes upon successful completion of the application process.  In addition the Company sold three vehicles for $33,000. 

  

Related to the Company’s loan, the Company made principal payments of $103,000 and $104,000$70,000 during the first ninesix months of 20182019 and 2017, respectively.  

2018.  During the first ninesix months of 2017, the Company received $2,000 from financing activities from the issuance of 250 shares of common stock due to the exercise of stock options while the2019, Company repurchased 26,9502,742 shares of its own stock during the first nine months of 2017 for $234,000.$21,000. 

    

A bank line of credit exists providing for borrowings of up to $2,050,000 and expiresexpired on SeptemberJune 30, 2019.  The line of credit was renewed and will expire on August 30, 2021.  The new line of credit is collateralized by the Company’s assets and bears interest at 1.8 percentage points over the 30-day LIBOR rate.  The Company did not utilize this line of credit during the first ninesix months of 20182019 or 2017,2018, and there were no borrowings outstanding as of SeptemberJune 30, 2018 and2019 or December 31, 2017.2018.  There are no financial covenants related to the line of credit. 

  

The Company believes that current financial resources, its line of credit, cash generated from operations and secured through debt financing, and short-term investments, along with the Company’s capacity for additional debt and/or equity financing will be sufficient to fund current and anticipated business operations.  The Company also believes that it is unlikely that a temporary decrease in demand for the Company’s products would impair the Company’s ability to fund operations given its excess cash and available line of credit.

17

credit expires.

  

Capital Expenditures 

  

Through the first ninesix months of 2018,2019, the Company incurred $501,000$231,000 of capital expenditures mainly for upgrades to the heating system at the Company’s main Duluth, Minnesota location, and for improvements to production and process capabilities.  capabilities and to replace two vehicles.

The Company expects additional capital expenditures in 20182019 of approximately $115,000$346,000 including an additional $25,000 relatedimprovements to the heating system upgrade.  The remaining 2018 capital expenditures are expected to be primarily for productionCompany's coating capabilities, process improvements and safety improvements.information technology upgrades.  Currently, the Company expects to fund its capital expenditures with existing cash and cash generated from operating activities. 

  

International Activity 

  

The Company markets its products to numerous countries in North America, Europe, Latin America, Asia and other parts of the world.  Foreign sales were approximately 29.3%29% of total sales during the first ninesix months of 20182019 compared to 32.8%28% of total sales forduring the first ninesix months of 2017.  Foreign sales in 2017 were favorably impacted by the sale of two DTX printers totaling $320,000 into Europe.  There were no DTX printer sales in 2018 and none are anticipated in the fourth quarter of 2018.  The fluctuations of certain foreign currencies have not significantly impacted the Company’s operations, as the Company’s foreign sales are not concentrated in any one region of the world, although a strong U.S. dollar does make the Company’s products less competitive internationally.  The Company believes its vulnerability due to uncertainties in foreign currency fluctuations and general economic conditions in foreign countries is not significant.

  

The Company’s foreign transactions are primarily negotiated, invoiced and paid in U.S. dollars, while a portion is transacted in Euros.  The Company has not implemented an economic hedging strategy to reduce the risk of foreign currency translation or transaction exposures, as management does not believe this to be a significant risk based on the scope and geographic diversity of the Company’s foreign operations as of SeptemberJune 30, 2018.2019.  Furthermore, the impact of foreign exchange on the Company’s balance sheet and operating results was not material in either 20182019 or 2017.2018.

  

Future Outlook 

  

IKONICS has spent an average of approximately 4.0% of annual sales in research and development and has made capital expenditures related to new products and programs.  The Company plans to maintain its efforts in these areas to expedite internal product development as well as to form technological alliances with outside entities to commercialize new product opportunities.

  

TheDespite lower sales for the first half of 2019, the Company continues to make progress on its AMS business initiative as demonstrated by its sales for the first nine months of 2018.business.  The Company has three long-term sales agreements in place for its technology with major aerospace companies.  In anticipation of this growing business, the Company increased its AMS capacity with a 27,300 square foot expansion at its Morgan Park site in 2016.

  

The Company is also continuing to pursue DTX-related business initiatives.  Despite lower sales for the first nine months of 2018, the Company expects increasing consumable sales as a result of the sale of two DTX printers in 2017.  However, additional DTX printer sales are not expected until 2019.  In addition to making efforts towards growing the inkjet technology business, the Company offers a range of products for creating texture surfaces and has introduced a fluid for use in prototyping.  The Company is currently working on production improvements as part of its joint development agreement with AKK, a German manufacturer of high quality printers, to enhance its customer offerings.  The Company has been awarded European, Japanese, and United States patents on its DTX technologies.  The Company has also modified its DTX technology to facilitate entry into the market for prototyping. 

 

Both the DomesticChromaline and IKONICS Imaging units remain profitable in mature markets. Although these business units require aggressive strategies to grow market share, both are developing new products and business relationships that we believethe Company believes will contribute to growth.  In October 2017, the Company introduced SubTHAT!™, a patent-pending product for the dye-sublimation market.  Response to SubTHAT!™ has been encouraging, howeverEarly in 2019 the Company fulfilledintroduced its new IKONART™ product to positive reviews and is generating sales.  IKONART™ provides a $258,000 SubTHAT!™ initial stocking order innew way to make custom reusable stencils for the fourth quarter of 2017 and does not expect to receive an order of that magnitude in 2018.creative arts markets.  In addition to its traditional emphasis on domestic markets, the Company will continue efforts to grow its business internationally by attempting to develop new markets and expanding market share where it has already established a presence. However, the strong U.S. dollar has made this challenging.

  

Other future activities undertaken to expand the Company’s business may include strategic partnerships, acquisitions, building improvements, equipment additions, new product development and marketing opportunities.

  

Recent Accounting Pronouncements 

 

During February 2016, the FASB issued ASU No. 2016-02, Leases.Leases. ASU No. 2016-02 was issued to increase transparency and comparability among organizations by recognizing all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. The Company is currently evaluating the impactadopted ASU No. 2016-02 as of January 1, 2019.  The adoption of this standard and doesdid not expect the adoption of ASU No. 2016-02 to have a material impact on its financial statements.

 

Off-BalanceOff Balance Sheet Arrangements 

  

The Company has no off-balance sheet arrangements.

  

ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk

  

Not applicable

  

ITEM 4.  Controls and Procedures

  

As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company’s disclosure control and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)).  Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

  

There waswere no change inchanges to the Company’sCompany's internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act that occurred during the period covered by this reportfirst six months of 2019 that has materially affected, or is reasonably likely to materially affect, the Company’sCompany's internal control over financial reporting.

 

 

PART II.OTHER INFORMATION

  

ITEM 1.

Legal Proceedings

  

None

  

ITEM 1A.

Risk Factors

  

Not applicable

  

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Not applicableThe Company repurchased shares as indicated in the table below during the second quarter of 2019(1)

 

          

(c) Total Number of

     
          

Shares Purchased

     
          

as

  

(d) Maximum Number

 
  

(a) Total Number

  

(b) Average

  

Part of Publicly

  

of Shares that May

 
  

of

  

Price

  

Announced Plans

  

Yet Be Purchased Under

 
  

Shares Purchased

  

Paid per Share

  

or Programs

  

The Plans or Programs

 

April 1, 2019 through April 30, 2019…………

    $       

May 1, 2019 through May 31, 2019…………

  2,189  $7.62   2,189   97,811 

June 1, 2019 through June 30, 2019………..

  553  $7.76   553   97,258 

(1) In 2017, the Company’s board of directors had authorized the repurchase of 100,000 shares of common stock.   A total of 33,500 shares have been repurchased under this program in prior years.  On April 29, 2019 the Company' board of directors approved an additional repurchase authorization of 33,500 shares of the Company's common stock bringing the total repurchase authorization to 100,000 shares of common.  A total of 36,242 shares have been repurchased under this program including the 2,742 share repurchased during the second quarter of 2019.  The plan allows for an additional 97,258 share to be repurchased.  The share repurchase authorizations do not have an expiration date.

ITEM 3.

Defaults upon Senior Securities

  

Not applicable

  

ITEM 4.

Mine Safety Disclosures

  

Not applicable

  

ITEM 5.

Other Information

  

None

  

ITEM 6.

Exhibits

  

The following exhibits are filed as part of this Quarterly Report on Form 10-Q for the quarterly period ended SeptemberJune 30, 2018:2019:

  

Exhibit

 

Description

3.1

 

Restated Articles of Incorporation of Company, as amendedamended. (Incorporated by reference to the like numbered Exhibit to the Company’s Registration Statement on Form 10-SB filed with the Commission on April 7, 1999 (File No. 000-25727).)

3.2

 

Amended and Restated By-Laws of the Company, as amended. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 30, 2018 (File No. 000-25757).)

31.1

 

Rule 13a-14(a)/15d-14(a) Certifications of CEO

31.2

 

Rule 13a-14(a)/15d-14(a) Certifications of CFO

32

 

Section 1350 Certifications

101

 

Interactive Data Files Pursuant to Rule 405 of Regulation S-T

  

Copies of Exhibits will be furnished upon request and payment of the Company’s reasonable expenses in furnishing the Exhibits.

 

IKONICS CORPORATION

  

SIGNATURES

  

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

 

IKONICS CORPORATION

 

 

 

 

DATE: NovemberAugust 13, 20182019

By:

/s/ Jon Gerlach

 

 

Jon Gerlach,

 

 

Chief Financial Officer, and

Vice President of Finance

  

2118